Novavax Inc

Novavax’s COVID‑19 vaccine strategy hinges on an FDA advisory vote, influencing its future VLP‑based products and investor sentiment.

Novavax’s Q1 2026 results reveal how its VLP tech and Matrix‑M adjuvant could reshape vaccine innovation, driving growth amid rising global health challenges.

Novavax faces a proxy battle as activist Shah Capital demands cost cuts, board shrinkage, and strategic review to unlock shareholder value.

Novavax’s turnaround: a profitable vaccine firm using VLP tech that’s climbing the Nasdaq, with strong earnings and growing investor interest.

Novavax insider purchase: director buys 8k shares and RSUs, showing strong confidence in VLP vaccine tech and future growth.

Novavax’s director boosts holdings, signaling confidence amid vaccine innovation and market volatility. Discover how this move reflects the company’s future prospects.

Novavax’s VLP vaccine tech is reshaping infectious disease prevention—learn how the biotech firm’s innovation and market traction promise safer, more effective vaccines.

Novavax faces activist pressure and seeks investor confidence amid a booming global COVID‑19 vaccine market, exploring strategy shifts to unlock growth.

Novavax Inc. is experiencing a surge in investor optimism due to a combination of activist investor engagement, analyst upgrades, and strategic partnerships, positioning the company for potential growth and increased valuation.

Novavax has expanded its collaboration with Sanofi, granting the French pharmaceutical company rights to use Novavax’s proprietary Matrix-M adjuvant in its pandemic influenza vaccine candidate program.